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Key messages
What is already known about this subject?
 ► Novel risk metrics such as JBS3 ‘heart age’ may 
identify patients with modest conventional cardio-
vascular risk scores who are at elevated lifetime 
risk.
 ► Patients with elevated levels of high-sensitivity C re-
active protein are recognised to be at increased car-
diovascular risk, and results of the recent CANTOS 
trial suggest clinical benefit in treating those with 
low-grade inflammation.
What does this study add?
 ► An additional ~40% of patients in this ‘at risk’ study 
cohort would be eligible for lipid-lowering therapy 
following the reduction of the National Institute for 
Health and Care Excellence treatment threshold 
from ≥20% to ≥10% 10-year cardiovascular disease 
(CVD) risk.
 ► A considerable proportion of those falling below this 
treatment threshold had an increased JBS3 ‘heart 
age’ as well as elevated levels of high-sensitivity C 
reactive protein.
How might this impact on clinical practice?
 ► Measurement of high-sensitivity C reactive pro-
tein in addition to the use of lifetime risk metrics 
may identify a substantial proportion of patients at 
greater absolute long-term cardiovascular risk than 
expected on the basis of their conventional 10-year 
risk scores. These individuals may benefit more 
from earlier intensive CVD prevention measures.
AbstrAct
Objectives This study assessed cardiovascular disease 
(CVD) risk classification according to QRISK2, JBS3 ‘heart 
age’ and the prevalence of elevated high-sensitivity C 
reactive protein (hsCRP) in UK primary prevention patients.
Method The European Study on Cardiovascular 
Prevention and Management in Usual Daily Practice 
(EURIKA) (NCT00882336) was a cross-sectional study 
conducted in 12 European countries. 673 UK outpatients 
aged ≥50 years, without clinical CVD but with at least one 
conventional CVD risk factor, were recruited. 10-year CVD 
risk was calculated using QRISK2. JBS3 ‘heart age’ and 
hsCRP level were assessed according to risk category.
Results QRISK2 and JBS3 heart age was calculated for 
285 of the 305 patients free from diabetes mellitus and 
not receiving a statin. QRISK2 classified 28%, 39% and 
33% of patients as low (<10%), intermediate (10% to 
<20%) and high (≥20%) risk, respectively. Two-thirds of 
low-risk patients and half of intermediate-risk patients 
had a heart age ≥5 years and ≥10 years higher than their 
chronological age, respectively. Half of low-risk patients 
had hsCRP levels ≥2 mg/L and approximately 40% had 
levels ≥3 mg/L. Approximately 80% of low-risk patients 
had both elevated hsCRP and heart age relative to their 
chronological age.
Conclusions Almost 40% more patients in this ‘at risk’ 
group would be eligible for statin therapy following the 
lowering of the National Institute for Health and Care 
Excellence treatment threshold to ≥10% 10-year risk. Of 
patients falling below this treatment threshold, almost all 
were at increased lifetime risk as measured by JBS3, and 
of these, the majority had elevated hsCRP levels. These 
patients with high absolute risk may benefit from early 
primary CVD prevention.
IntROduCtIOn
Cardiovascular disease (CVD) is a major 
health concern. It is the leading cause of 
mortality in Europe and accounts for a third 
of all deaths in the UK.1 2 Multiple interacting 
risk factors contribute to the development of 
CVD.3 Well-established risk factors include old 
age, male sex, smoking, elevated cholesterol 
levels, hypertension and diabetes mellitus.3
Cardiovascular risk assessment is routinely 
performed to assess an individual’s risk of 
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CVD events and to guide preventive treatment strategies. 
The most frequently used risk algorithm is the QRISK2 
risk assessor, which is calibrated using UK patient data 
and assesses an extensive array of risk factors, incorpo-
rating body mass index (BMI), ethnicity, an area of resi-
dence–based deprivation index, type 2 diabetes mellitus, 
antihypertensive treatment status, family history of CVD, 
chronic kidney disease, atrial fibrillation and rheuma-
toid arthritis into the algorithm.4 This method provides 
an estimation of the 10-year risk of experiencing a CVD 
event and is widely used in the primary care setting.5 The 
JBS3 risk calculator released in the Joint British Soci-
eties’ CVD prevention guidelines in 20146 was developed 
from the QRISK2 lifetime cardiovascular risk algorithm. 
JBS3 provides novel lifetime risk metrics including ‘heart 
age’, which indicates the age of an individual of the same 
gender and ethnicity with an equivalent annual risk of 
a cardiovascular event but with an optimal risk factor 
profile.6
Assessment of global cardiovascular risk is recom-
mended for identification of patients likely to benefit 
most from medical intervention as part of CVD primary 
prevention.3 5 6 European guidelines for CVD preven-
tion recommend concurrent assessment of both choles-
terol levels and 10-year CVD risk when considering 
commencing antihypertensive or lipid-lowering therapy 
in apparently healthy, asymptomatic individuals.3 
National Institute of Health and Care Excellence (NICE) 
guidance on CVD risk assessment and lipid modification 
published in 2014 lowered the threshold for initiation 
of lipid-lowering therapy from ≥20% 10-year CVD risk 
to include individuals at ≥10% risk, potentially greatly 
increasing the number eligible for statin treatment in 
primary CVD prevention.5
In addition to established CVD risk factors, patients with 
elevated plasma levels of inflammatory biomarkers, such as 
high-sensitivity C reactive protein (hsCRP), are recognised 
to be at increased cardiovascular risk.7 A continuous asso-
ciation exists between CRP level and risk of cardiovascular 
events,8 remaining significant after adjustment for conven-
tional risk factors.7 9 10 Furthermore, inclusion of hsCRP 
data into risk models enhances the predictive value of 
established risk factors.9 11 12 Measurement of hsCRP may 
therefore be useful in identifying individuals at higher 
risk of cardiovascular risk than predicted by traditional 
risk algorithms, although not used routinely in the UK 
and Europe. Improving the accuracy of CVD risk assess-
ment remains a major priority in the primary prevention 
of CVD given that one-fifth or more of all cardiovascular 
events occur in those without major conventional CVD 
risk factors,13 and half of all myocardial infarctions and 
strokes occur in individuals with a lipid profile which 
might not warrant therapeutic intervention under estab-
lished guidelines.14 The JUPITER study and more recent 
CANTOS study have  shown that both rosuvastatin 20 mg 
daily and treatment with a novel anti-interleukin 1 mono-
clonal antibody can improve clinical outcomes in those 
patients with evidence of low-grade inflammation.14 15
We conducted a post hoc analysis of the UK cohort 
of the European Study on Cardiovascular Risk Preven-
tion and Management in Usual Daily Practice (EURIKA; 
ClinicalTrials. gov identifier: NCT00882336), a cross-sec-
tional study conducted to assess the management of 
cardiovascular risk factors in primary care in Europe.16 
Our study explored the potential clinical impact of using 
more contemporary CVD risk assessment strategies risk 
for primary prevention in a representative real-world 
patient population and how introduction of the recent 
NICE guidance criteria for lipid modification5 might 
further change clinical decision-making. We first assessed 
CVD risk assessment according to QRISK2 (2017) in 
those without diabetes and not already commenced on 
lipid-lowering therapy. Second, we considered the poten-
tial of ‘heart age’, an indicator of lifetime risk, in further 
guiding preventative strategies in these patients. We also 
assessed the prevalence of elevated hsCRP levels in rela-
tion to CVD risk classification.
MetHOd
Study design and participants
The EURIKA study ( ClinicalTrials. gov identifier: 
NCT00882336) was a cross-sectional study conducted 
in 12 European countries (Austria, Belgium, France, 
Germany, Greece, Norway, Russia, Spain, Sweden, Switzer-
land, Turkey and the UK). The study protocol has been 
described in detail elsewhere.16 In brief, approximately 
60 physicians were randomly selected from each country 
using the OneKey Healthcare Professional Database and 
were stratified by age, sex and specialty. Physicians from 
specialties involved in cardiovascular disease risk control 
were considered for selection. This included primary care 
physicians, cardiologists, endocrinologists and internal 
medicine specialists. Patients attending outpatient appoint-
ments who met the selection criteria (online supplemen-
tary appendix 1) were invited consecutively to participate 
in the study. Patients recruited were at least 50 years of age 
and free from clinical CVD, but with at least one classical 
risk factor (dyslipidaemia, hypertension, smoking, diabetes 
mellitus or obesity). Hypertension was defined as blood 
pressure ≥140/90 mm Hg and ≥130/80 mm Hg for those 
with diabetes mellitus. Patients receiving antihypertensive 
medication following a previous diagnosis of hyperten-
sion were also considered hypertensive. Dyslipidaemia was 
defined as total cholesterol ≥5 mmol/L or low-density lipo-
protein (LDL)-cholesterol ≥4.5 mmol/L. Similarly, patients 
with a prior diagnosis of dyslipidaemia who were receiving 
lipid-lowering therapy were also classed as having dyslipi-
daemia. Diabetics were considered to be dyslipidaemic if 
total cholesterol ≥4.5 mmol/L or LDL-cholesterol ≥2.5 
mmol/L.17
Patient information was gathered via clinical records, 
physical examination and a 12-hour fasting blood sample, 
which was collected within 1 day of the outpatient 
consultation. Laboratory analyses were conducted in a 
centralised laboratory.16 Additionally, a patient-specific 
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Table 1 Baseline characteristics for the entire UK cohort, for patients free from diabetes and not receiving astatin, and 
according to QRISK2 (2017) 10-year cardiovascular risk
Overall (N=673)
Patients without 
DM who were not 
receiving statin 
treatment (N=305)
Low risk (<10%)
(N=80)
Intermediate risk
(10% to <20%)
(N=110)
High risk
(≥20%)
(N=95)
Age, years 65.0 (8.9) 64.4 (9.4) 55.6 (4.6) 62.5 (5.6) 72.7 (6.9)
Men, n (%) 344 (51.1) 135 (44.3) 19 (23.8) 55 (50) 54 (56.8)
Dyslipidaemia, n (%) 357 (53.0) 68 (22.3) 21 (26.3) 23 (20.9) 19 (20.0)
Total cholesterol, mmol/L 5.0 (1.2) 5.7 (1.0) 5.7 (0.9) 5.7 (1.1) 5.7 (1.0)
LDL-C, mmol/L 2.9 (1.0) 3.5 (0.8) 3.4 (0.7) 3.5 (0.9) 3.5 (0.9)
HDL-C, mmol/L 1.4 (0.4) 1.5 (0.4) 1.6 (0.5) 1.5 (0.4) 1.5 (0.4)
Triglycerides, mmol/L 1.7 (0.9) 1.6 (0.9) 1.4 (0.6) 1.6 (0.8) 1.7 (1.1)
Hypertension, n (%) 481 (71.5) 223 (73.1) 44 (55.0) 84 (76.4) 84 (88.4)
SBP, mm Hg 136.3 (15.9) 137.2 (15.6) 128.7 (13.5) 137.8 (14.7) 143.9 (14.6)
DBP, mm Hg 79.1 (9.9) 80.1 (10.1) 80.5 (9.3) 82.3 (10.1) 78.3 (9.8)
DM, n (%) 152 (22.6) 0 (0) 0 (0) 0 (0) 0 (0)
BMI, kg/m2 29.3 (6.4) 28.6 (6.2) 28.9 (6.2) 29.1 (5.1) 28.5 (4.9)
Obese, n (%) 239 (35.5) 97 (31.8) 31 (38.8) 35 (31.8) 26 (27.4)
Current smoker, n (%) 110 (16.3) 56 (18.4) 40 (50.0) 49 (44.5) 52 (54.7)
HsCRP, mg/L, median (IQR) 2.1 (3.4) 2.4 (3.6) 2.1 (4.7) 2.8 (4.1) 2.3 (2.7)
Data are mean (SD) unless otherwise indicated.
BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-
sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure.
questionnaire was used to collect sociodemographic data 
and information relating to CVD risk factors and current 
medications.
A total of 7641 patients were enrolled in the study 
across Europe. Six hundred seventy-three UK patients 
were selected by 69 participating UK physicians. In the 
present analysis, only patients with hsCRP levels avail-
able were considered (672/673). Subjects with diabetes 
mellitus (already considered at risk regardless of hsCRP 
level) and those already receiving a statin (for whom a 
treatment decision has already been made) were also 
excluded from analysis. Three hundred five patients were 
free from diabetes mellitus and not receiving a statin, of 
whom data were available for calculation of QRISK2 CVD 
risk score in 285.
Conventional cardiovascular risk classification
Participants’ 10-year cardiovascular risk was initially 
assessed by the conventional CVD risk calculator QRISK2 
(2017 version).4 QRISK2 risk categories were <10% low 
risk, 10% to <20% intermediate risk and ≥20% high risk.
JBS3 heart age
Heart age was calculated using the JBS3 online risk 
assessment tool18 between 26 April and 11 May 2016. The 
difference between heart age and chronological age was 
calculated. The JBS3 algorithm could model a maximum 
heart age of 95 years. A total 53 subjects had heart ages 
exceeding this upper limit when the algorithm was 
applied. For the purpose of estimation of heart age, aver-
ages, differences between heart age and chronological 
age, and classification, these subjects were considered as 
having a heart age of 95 years.
Assessment of hsCRP levels
CRP levels were measured in a central core laboratory by 
a high-sensitivity immunoturbidimetry method (Roche 
P-Modular). HsCRP levels were categorised according to 
cardiovascular risk category. The thresholds for classifying 
hsCRP levels were set according to both American Heart 
Association/Centers for Disease Control and Pguidelines 
(those with hsCRP <1 mg/L should be considered low 
risk, hsCRP 1 to <3 mg/L as intermediate and ≥3 mg/L 
as high risk),7 and also according to JUPITER study selec-
tion criteria (those with hsCRP >2 mg/L would have been 
eligible for recruitment).14 HsCRP levels were available for 
all 285 for whom QRISK2 CVD risk could be calculated.
Statistical analysis
Statistical analysis was carried out using IBM SPSS Statis-
tics V.20.
ReSultS
demographics and baseline characteristics
Subject demographics and baseline characteristics for 
the entire UK cohort, those free from diabetes mellitus 
and not receiving a statin, are shown in table 1.
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Figure 1 High-sensitivity C reactive protein (hsCRP) levels 
in the total UK cohort.
Figure 2 High-sensitivity C reactive protein (hsCRP) levels 
according to cardiovascular disease risk as calculated by 
QRISK2 in patients free from diabetes and not receiving a 
statin.
Figure 3 Difference between JBS3 ‘heart age’ and 
chronological age for cohort and according to QRISK2 10-
year cardiovascular disease risk category.
The mean age of the entire cohort was 65 years and 
51.1% were men. Over 22.6% (152) had diabetes 
mellitus, approximately 70% were hypertensive, over 
half had dyslipidaemia and approximately 35% were 
obese (mean BMI ~30 kg/m2). The baseline character-
istics of subjects without DM and not receiving a statin 
were otherwise very similar to the overall cohort, except 
a lower proportion had a prior diagnosis of dyslipidaemia 
(22.3 vs 53.0%; p≤0.0001).
HsCRP levels
HsCRP levels were available for 672 out of 673 of the 
overall UK study group and 304 out of the 305 patients 
without diabetes who were not receiving statin treatment. 
The median hsCRP level for the overall UK population 
was 2.1 mg/L. The 305 patients without diabetes who 
were not receiving statins had a median hsCRP of 2.4 
mg/L. Approximately half of all the UK patients had 
hsCRP levels ≥2 mg/L and over one-third of all patients 
had hsCRP ≥3 mg/L (figure 1).
QRISK2 10-year CVd risk
The median 10-year QRISK2 score was 15% (IQR 13.85). 
QRISK2 classified 28% (n=80) of patients as low (<10%), 
39% (n=110) as intermediate (10% to <20%) and 33% 
(n=95) as high (>20%) 10-year CVD risk.
HsCRP levels according to QRISK2 category
HsCRP levels in relation to QRISK2 category are shown 
in figure 2. In the subgroup of patients without diabetes 
and not receiving statin treatment, 41.4% had hsCRP 
levels ≥3 mg/L. Moreover, ≥50% of patients in each risk 
category had hsCRP levels ≥2 mg/L; 41.3% of low-risk 
patients had a hsCRP ≥3 mg/L and 50.0% had a hsCRP 
≥2 mg/L.
Heart age
Heart ages expressed in relation to chronological age 
according to QRISK2 are displayed in figure 3 (online 
supplementary table 1) for the 285 patients without 
diabetes or taking a statin. Their median heart age was 
73.0 years (IQR 18.5 years), and they had a median heart 
age 10.0 years greater than their chronological age. The 
heart age of all but two of these patients (>99%) exceeded 
their chronological age, of whom 16.3% (n=46) had a 
heart age between 0 and 5 years greater, 29.3% (n=83) 
between 5 and 10 years greater, 24.9% (n=71) +10 and 15 
years greater, and 29.3% (n=83) ≥15 years greater than 
their chronological age.
When assessed in relation to QRISK2 risk, two-thirds of 
low-risk patients and 85.5% of intermediate-risk patients 
had heart ages ≥5 years greater than their age. Also, 
18.8% of low-risk patients and 53.6% of intermediate-risk 
patients had heart ages ≥10 years greater than their age.
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Figure 4 High-sensitivity C(hsCRP) levels according to 
difference between JBS3 ‘heart age’ and chronological age.
Heart age and hsCRP
The distribution of hsCRP levels within heart age catego-
ries is shown in figure 4. Moreover, 159 of 285 patients 
without diabetes mellitus or statin treatment (55.8%) 
had elevated heart age and hsCRP levels ≥2 mg/L. Of the 
80 patients classified as low risk by QRISK2, 63 (78.8%) 
had both increased heart age relative to age and elevated 
hsCRP levels (≥1 mg/L); 40 of these patients (50.0%) 
had both increased heart age and hsCRP levels ≥2 mg/L 
(online supplementary table 1).
dISCuSSIOn
In this analysis of data from the UK cohort of the EURIKA 
study of patients over the age of 50 and with at least one 
major CVD risk factor, free from diabetes and not taking 
a statin, we found that a third of patients were classified 
as high risk by QRISK2, the conventional cardiovascular 
risk calculator used in the UK, and therefore eligible 
for statin therapy using a conventional ≥20% treatment 
threshold at the time of the EURIKA study data collec-
tion, which occurred between May 2009 and January 
2010.16 However, given the further lowering of the treat-
ment threshold for initiation of lipid-lowering therapy in 
the 2014 NICE guidance to an estimated 10-year CVD risk 
of ≥10%,5 we estimate that almost an additional 40% of 
untreated patients ≥50 years old with at least one major 
risk factor would have been eligible for high-intensity 
statin treatment. Only ~30% of this population would 
have been considered low risk and ineligible for statin 
treatment according to NICE guidance.5
The 2014 JBS3 recommendations emphasise the 
need for greater focus on lifetime CVD risk assessment, 
given that the majority of cardiovascular events occur 
in those identified as intermediate risk as assessed by 
conventional 10-year risk scoring systems.6 JBS3 also 
highlights that short-term risk measures often fail to iden-
tify younger patients, especially women, who may be at 
considerable lifetime exposure to modifiable CVD risk 
factors but with modest short-term risk scores, and could 
derive benefit from early risk factor management as part 
of primary prevention. This has led to the introduction 
of risk metrics such as ‘heart age’, incorporated in the 
JBS3 tool, which aim to quantify this lifetime risk and aid 
clinical decision-making and communication of risk with 
patients. Our data demonstrate that in low-risk and inter-
mediate-risk patients with at least one major risk factor, 
significant proportions have a predicted JBS3 ‘heart age’ 
of at least 5 and even 10 years or more higher than their 
chronological ages. While the threshold for considering 
a heart age to be significant relative to age may not easily 
be defined in absolute terms, it may be appropriate to 
consider this measure when considering whether to 
initiate drug therapy if there is uncertainty or after life-
style interventions have been unsuccessful.
Results from our analysis demonstrate that a large 
proportion of patients have clinically relevant elevation 
in hsCRP levels. This applies across all 10-year risk catego-
ries as assessed by QRISK2. Previous work using data from 
the entire European EURIKA cohort identified similar 
proportions of patients with elevated hsCRP across risk 
categories when applying Systematic Coronary Risk Eval-
uation (SCORE) and Framingham Risk (FRS) Scores for 
CVD risk assessment.19 For clinical decision-making, this 
has previously been most relevant in patients classified as 
intermediate risk by conventional methods.20 Although 
not routinely used in the UK, the recent lowering of the 
threshold for considering initiation of statin treatment 
by NICE has further weakened the argument for the 
measurement of hsCRP in intermediate-risk UK patients. 
Nonetheless, identification of elevated hsCRP still iden-
tifies a population for whom a greater absolute benefit of 
statin therapy might be realised than would otherwise be 
expected based on their traditional risk factor profile.
The JUPITER trial demonstrated a 44% reduction in 
cardiovascular events in patients receiving rosuvastatin 
20 mg, all of whom had elevated hsCRP levels but a lipid 
profile that would not warrant statin therapy according 
to contemporary US clinical guidelines (LDL-choles-
terol <3.4 mmol/L).14 Indeed, rosuvastatin almost halved 
major CVD events in those with a 10-year CVD risk of 
5%–10% by Framingham Risk Score. A prospective study, 
conducted in a more general UK population, identified 
approximately one-fifth of study participants as quali-
fying for medical therapy under JUPITER criteria who 
would not be candidates according to established scoring 
systems, and these subjects had a significantly increased 
event rate (HR 1.70).21 Our results reveal a considerable 
proportion of low-risk patients in the UK (≥50 years with 
one conventional risk factor) with elevated hsCRP levels 
who may therefore be at higher CVD risk than would be 
predicted based on conventional assessment methods 
and who may derive greater absolute clinical benefit from 
statin therapy with greater cost-effectiveness. However, 
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these numbers would be smaller than those newly eligible 
through lowering of the conventional CVD risk score 
threshold from ≥20% to ≥10%.
It may be useful to consider lifetime risk metrics such as 
heart age in conjunction with biomarkers such as hsCRP 
to identify those who are both at significant long-term 
cardiovascular risk based on their traditional risk factors 
in addition to an elevated level of background vascular 
inflammation. The results of the recent CANTOS trial 
demonstrated a significant reduction in cardiovascular 
events in patients with previous myocardial infarction and 
hsCRP levels >2 mg/L who were randomised to receive 
monoclonal antibody targeted to reduce serum IL-1β 
and hsCRP levels without modification of lipid profile.15 
Although the CANTOS study was in a secondary preven-
tion population, it has added further weight to the inde-
pendent role of inflammation in atherosclerosis and the 
use of inflammatory biomarkers in identifying those at 
risk of future events who may benefit from early interven-
tion. Of note, almost half of patients with a low QRISK2 
score within our study population who had a heart age 
greater than their chronological age also had hsCRP 
levels greater or equal to the JUPITER and CANTOS 
threshold of 2 mg/L and might potentially benefit from 
a more intensive CVD risk-lowering treatment strategy.
The strengths of the EURIKA study protocol are the 
standardisation of data collection and the use of a central 
laboratory for blood analyses (including hsCRP assays).16 
Furthermore, the inclusion of physicians from a variety 
of medical specialties and the consecutive selection of 
eligible patients is likely to have provided a broad repre-
sentation of such UK patients. It is possible, however, 
that the brevity of the recruitment period (3 months) 
may have biased selection towards less healthy, frequent 
users of healthcare services, who may have higher levels 
of hsCRP.
In conclusion, our analysis of data from UK patients 
aged 50 years or more with at least one cardiovascular 
risk factor has shown that an additional 40% of untreated 
patients within this ‘at risk’ cohort may be eligible for 
statin initiation following the reduction in the treatment 
threshold by NICE to ≥10% 10-year CVD risk. A consid-
erable number of patients with low or intermediate risk 
scores had a heart age, as modelled by JBS3, greater than 
their chronological age and may be at greater lifetime 
risk than reflected by their 10-year risk score. Addition-
ally, a large proportion of patients aged 50 years or more 
with at least one CVD risk factor have elevated hsCRP 
levels. Measurement of hsCRP in patients classified as 
low risk in conjunction with lifetime risk metrics such as 
heart age may further identify a substantial proportion of 
patients who are at higher risk than might otherwise be 
predicted by conventional metrics and who may derive 
greater absolute clinical benefit from statin therapy at 
greater cost-effectiveness.
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